Olmesartan/Amlodipino/Hidroclorotiazida Lacer (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipino/Hidroclorotiazida Lacer, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination tablet for oral use. It is employed in the management of hypertension, often in patients who require additional blood pressure control beyond monotherapy. GNH USA supplies Olmesartan/Amlodipino/Hidroclorotiazida Lacer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Amlodipino/Hidroclorotiazida Lacer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipino/Hidroclorotiazida Lacer is indicated for hypertension and related cardiovascular risk management. - Hypertension: provides additional blood pressure reduction when monotherapy is insufficient. - Hypertensive heart disease: helps lower cardiac after‑load and improve ventricular function. - Chronic kidney disease with hypertension: assists in slowing progression of renal impairment associated with high blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of the lower limbs. - Dizziness or light‑headedness, especially on standing. - Flushing: transient warmth or redness of the skin. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Angio‑edema: swelling of the face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte disturbances: significant changes in potassium or sodium levels. - Acute kidney injury: sudden reduction in renal function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Blood dyscrasias: rare blood cell abnormalities.

When prescribing this combination, clinicians should consider several safety aspects. - Renal function monitoring: assess baseline creatinine and eGFR before initiation and periodically thereafter. - Electrolyte balance: check serum potassium and sodium, especially when combined with other diuretics. - Pregnancy contraindication: avoid use in pregnancy due to fetal toxicity. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Drug‑specific ​   - Store at  

Potential  

--- ---  

  \n    \\